Clinical trials: Vascular Endothelial Growth Factor, open to volunteers
Acute Kidney Injury, Cardiac Surgery Associated - Acute Kidney Injury
Perioperative Role Of Vascular Endothelial Growth Factor In Cardiac Surgery-associated Acute Kidney Injury
The goal of this prospective observational study is to find out whether the protein vascular endothelial growth factor (VEGF) measured in blood and urine can predict which patients will develop acute kidney injury (AKI) after…
- Trial name
- PROVE-AKI (NCT07803328)
- Where
- Germany
- Volunteers
- 220 people
- Sponsor
- Universität Münster
Advanced Solid Tumor Cancer
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase…
- Trial name
- NCT04777994
- Testing
- ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor
- Where
- 30 sites in United States, France and 4 more
- Volunteers
- 248 people
- Sponsor
- Calico Life Sciences LLC
Vascular Anomaly, Generalized Lymphatic Anomaly
Identification of Biomarkers for Patients with Vascular Anomalies
The study will use blood (serum and plasma) and tissue obtained from participants undergoing prescribed surgical resection of vascular anomalies of interest proposed in this study.
- Conditions
- Vascular Anomaly, Generalized Lymphatic Anomaly, Kaposiform Hemangioendothelioma, Kaposiform Lymphangiomatosis
- Trial name
- NCT03001180
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cholangiocarcinoma, Bile Duct Neoplasm
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
Background: Cholangiocarcinoma (CCA) is an aggressive cancer of the bile ducts. People with CCA have few treatment options and poor survival. Researchers want to see if a new drug can stop or slow CCA growth.
- Conditions
- Cholangiocarcinoma, Bile Duct Neoplasm, Biliary Tract Malignancy
- Trial name
- NCT04645160
- Testing
- Tivozanib
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Extensive-stage Small-cell Lung Cancer
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for…
- Trial name
- NCT06712355
- Testing
- Pumitamig, Atezolizumab, Etoposide
- Where
- 225 sites in United States, Australia and 12 more
- Volunteers
- 621 people
- Sponsor
- BioNTech SE
Non-small Cell Lung Cancer
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
This is a Phase II, multisite, open-label study consisting of two parts in participants with advanced/metastatic Non-small Cell Lung Cancer (NSCLC) which progressed after a first-line chemoimmunotherapy to evaluate the…
- Trial name
- NCT06841055
- Testing
- Pumitamig, Docetaxel
- Where
- 30 sites in United States, Australia and 4 more
- Volunteers
- 60 people
- Sponsor
- BioNTech SE
Renal Function Disorder, Diabetic Macular Edema (DME)
Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients
This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients.
- Conditions
- Renal Function Disorder, Diabetic Macular Edema (DME), Neovascular Age Related Macular Degeneration
- Trial name
- NCT06929507
- Testing
- Intravitreal injection of Faricimab or Aflibercept 2 mg
- Where
- 2 sites in Greece
- Volunteers
- 60 people
- Sponsor
- University Hospital, Alexandroupolis
Recurrent Glioblastoma
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
This multi-site Phase II study will enroll adults with histologically confirmed diagnosis of World Health Organization (WHO) Grade IV glioblastoma (GBM), isocitrate dehydrogenase (IDH)-wildtype consistent with WHO central nervous…
- Trial name
- NCT07297212
- Testing
- Pumitamig, Bevacizumab, Temozolomide
- Where
- 6 sites in China
- Volunteers
- 75 people
- Sponsor
- BioNTech SE
Age-related Macular Degeneration (ARMD), Choroidal Neovascularization
Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization
Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly…
- Conditions
- Age-related Macular Degeneration (ARMD), Choroidal Neovascularization, Anti-vascular Endothelial Growth Factor
- Trial name
- NCT07187804
- Testing
- Intravitreal faricimab injection
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Kim's Eye Hospital
Severe Diabetic Macular Oedema
Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns
The macula is the centre of the retina; it gives central sight, colour and fine detail. People with diabetes may develop diabetic macular oedema (DMO).
- Trial name
- DAME (NCT06985706)
- Testing
- Subthreshold Micropulse Laser (SML), Anti-VEGF Monotherapy (standard care)
- Where
- 22 sites in United Kingdom
- Volunteers
- 264 people
- Sponsor
- Belfast Health and Social Care Trust
Gastrointestinal Carcinoma, Dysplasia
Study of VEGF-A Targeting NIR-II Fluorescence Endoscopy in the Gastrointestinal Tract
In this study, the investigators are studying new ways to look for abnormal tissues of the gastrointestinal tract during an endoscopy.
- Conditions
- Gastrointestinal Carcinoma, Dysplasia, Gastrointestinal Polyp
- Trial name
- NCT06430372
- Testing
- Bev-ICG, NIR-II fluorescence endoscopy platform
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Automation, Chinese Academy of Sciences
Hepatocellular Carcinoma, Immunotherapy
Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
Through a retrospective study of patients who underwent comprehensive treatment for hepatocellular carcinoma at the Second Affiliated Hospital of Zhejiang University, we explored the risk factors related to the sensitivity of…
- Trial name
- NCT06542796
- Testing
- Immunotherapy combined with targeted therapy, Standard treatment plan
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
IC, Hunner Type Interstitial Cystitis
The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis With Hunner's Lesions
To evaluate the efficacy and safety of Neovasculgen in interstitial cystitis with Hunner's lesions to reduce cicatricial changes in the bladder caused by electrocoagulation and to prevent secondary bladder shrinkage with a…
- Conditions
- IC, Hunner Type Interstitial Cystitis, Bladder Pain Syndrome
- Trial name
- NCT07459790
- Testing
- Neovasculgen®
- Where
- Russia
- Volunteers
- 180 people
- Sponsor
- JSC NextGen
HCC - Hepatocellular Carcinoma
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
This trial is designed to explore the efficacy and safety of interventional therapy combined with immune checkpoint inhibitors(ICIs) and anti-vascular endothelial growth factor(VEGF) antibody/tyrosine kinase inhibitors in the…
- Trial name
- NCT07157969
- Testing
- Lenvatinib, Pembrolizumab, Atezolizumab
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Rheumatoid Arthritis
Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation of the joints, leading to pain, swelling, disability, and reduced quality of life.
- Trial name
- NCT07497282
- Testing
- venlafaxine extended-release (XR), Standard conventional Rheumatoid Arthritis Therapy
- Volunteers
- 70 people
- Sponsor
- Ain Shams University
Renal Cell Carcinoma
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03).
- Trial name
- NCT07049926
- Testing
- Belzutifan, Zanzalintinib
- Where
- 33 sites in United States, Chile and 6 more
- Volunteers
- 140 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC).
- Trial name
- NCT06712316
- Testing
- Pumitamig, Pembrolizumab, Carboplatin
- Where
- 366 sites in United States, Argentina and 20 more
- Volunteers
- 1,580 people
- Sponsor
- BioNTech SE
Retinopathy of Prematurity (ROP), Prematurity Complications
Retinopathy of Prematurity - Visual Function and Retinal Structure
Children born prematurely may develop a characteristic retinal disease named retinopathy of prematurity (ROP). This disease could lead to retinal detachment and blindness.
- Conditions
- Retinopathy of Prematurity (ROP), Prematurity Complications, Cerebral Visual Impairment, Visual Field Defect
- Trial name
- NCT07427719
- Where
- Norway
- Volunteers
- 140 people
- Sponsor
- Oslo University Hospital
Hepatocellular Carcinoma
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic effect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular…
- Trial name
- ZENOBIA (NCT06698250)
- Testing
- Zanzalintinib, Durvalumab, Tremelimumab
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Anwaar Saeed
IC, Interstitial Cystitis and Bladder Pain Syndrome
The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis Without Hunner's Lesions.
To evaluate the efficacy and safety of Neovasculgen in interstitial cystitis and the prevention of secondary bladder shrinkage with a decrease in its volume.
- Conditions
- IC, Interstitial Cystitis and Bladder Pain Syndrome, Interstitial Cystitis, Chronic
- Trial name
- NCT07391306
- Testing
- Neovasculgen®
- Where
- Russia
- Volunteers
- 180 people
- Sponsor
- JSC NextGen